Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report

Gynecologic CancerRadio-Oncology

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Lancet.

Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ

doi: 10.1016/

Gynecologic Cancer

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Lancet Oncol.

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators

doi: 10.1016/

Genitourinary Cancer

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

J Immunother Cancer.

Cabel L, Loir E, Gravis G, Lavaud P, Massard C, Albiges L, Baciarello G, Loriot Y, Fizazi K

doi: 10.1186/s40425-017-0232-7.

Gynecologic Cancer

Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion

J Natl Compr Canc Netw.

Randall M, Burgess K, Buckingham L, Usha L

doi: 10.6004/jnccn.2019.7378.

Lymphoma

Nivolumab maintenance after salvage autologous stem cell transplantation results in long term remission in multiple relapsed primary cns lymphoma

Eur J Haematol.

Terziev D, Hutter B, Klink B, Stenzinger A, Stögbauer F, Glimm H, Fröhling S, Wickenhauser C, Jordan K, Hurtz HJ, Müller LP, Rüssel J, Weber T

doi: 10.1111/ejh.13072.

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Gastrointestinal Cancer

Multidisciplinary Approach to a Patient with Acinar Cell Carcinoma, a Rare Pancreatic Malignancy

healthbook Times Oncology Hematology

Palmarocchi MC, Merlo E, Cefali M, De Dosso S

doi: 10.36000/hbT.OH.2021.07.029

Gynecologic Cancer

Effective treatment of a patient with stage IV ovarian cancer: A case report

Oncol Lett.

Huang Z, Yan H, Chavan D, Yuan Z, Yang X, Zhang Y, Song K, Kong B

doi: 10.3892/ol.2017.7285.

Endocrine and Neuroendocrine Tumors (NET)Skin Cancer

Long-Term Sustained Disease Control With Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma

healthbook TIMES Oncology Hematology

Zihlera D, Vollmera K, Cozzio A

doi: 10.36000/hbT.OH.2019.01.003

Related content

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion

Nivolumab maintenance after salvage autologous stem cell transplantation results in long term remission in multiple relapsed primary cns lymphoma

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

Multidisciplinary Approach to a Patient with Acinar Cell Carcinoma, a Rare Pancreatic Malignancy

Effective treatment of a patient with stage IV ovarian cancer: A case report

Long-Term Sustained Disease Control With Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma